Join our daily newsletter At The Bell to receive exclusive market insights
- Anteris Technologies (AVR) implants five TAVR patients in a first-in-human study to treat severe aortic stenosis in Georgia
- The study aimed to assess the DurAVR THV system for treating the disease, with the transcatheter aortic valve replacement (TAVR) procedures pronounced successful and without complications by Anteris
- The company says the first five patients go a long way in proving the unique benefits of the DurAVR valve, validating its prior preclinical work
- An additional five patients are planned for treatment in the first quarter of 2022 to conclude the study
- Anteris Technologies is up 13.7 per cent, trading at $10.10 at 2:50 pm AEDT
Anteris Technologies (AVR) has implanted five TAVR patients in a first-in-human study to treat severe aortic stenosis in Georgia.
The study aimed to assess the DurAVR THV system for treating the disease, which sees a patient’s heart’s aortic valve narrow, reducing blood flow from the heart to the main artery of the body.
The trial looked to determine the correct positioning of the DurARV valve in the proper anatomical location, as well as haemodynamic performance, assessed after both 30 days and one year. DurAVR is a 3D single-piece aortic valve for the treatment of aortic stenosis.
The transcatheter aortic valve replacement (TAVR) procedures were all pronounced successful by Anteris, and without complications.
The company said the first five patients go a long way in proving the unique benefits of the DurAVR valve and validating the prior preclinical work, with results to date looking better than anticipated.
“In this early experience, DurAVR showed superior haemodynamic with some of the largest effective orifice areas I have seen in any TAVR platform,” Dr Paul Sorajja, Medical Advisory board member of Anteris said.
“Remarkably, this was observed with rapid deployment techniques and standard implant depths and in small aortic annular areas. Importantly, there were no adverse events.
“This technology allows us to provide superior haemodynamic with a balloon expandable platform.”
An additional five patients are planned for treatment in the first quarter of 2022 to conclude the study.
Anteris Technologies was up 13.7 per cent, trading at $10.10 at 2:50 pm AEDT.
